Masanori P Takahashi
Overview
Explore the profile of Masanori P Takahashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
1862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watanabe G, Takai Y, Nagane Y, Kubota T, Yasuda M, Akamine H, et al.
Front Immunol
. 2025 Jan;
15:1502721.
PMID: 39763650
International consensus guidance and Japanese clinical guidelines for myasthenia gravis (MG) recommend achieving minimal manifestations or better status (MM-or-better) as the severity component of the treatment goal. However, the subjective...
2.
Kamon M, Wakatsuki S, Nakamori M, Takahashi M, Mori-Yoshimura M, Komaki H, et al.
Hum Mol Genet
. 2024 Dec;
34(4):327-337.
PMID: 39679849
Myotonic dystrophy type 1 (DM1) is a dominantly inherited multi-system disease caused by expanded CTG repeats in the 3' untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. Similar...
3.
Yasuda M, Uzawa A, Kuwabara S, Suzuki S, Akamine H, Onishi Y, et al.
J Neuroimmunol
. 2024 Oct;
397:578465.
PMID: 39454316
No abstract available.
4.
Itoh H, Hisamatsu T, Segawa K, Takahashi T, Sato T, Takada H, et al.
Eur Heart J Open
. 2024 Oct;
4(5):oeae078.
PMID: 39391712
Aims: Myotonic dystrophy Type 1 (DM1) is caused by the expansion of CTG repeats (CTGn) in the DM1 protein kinase (DMPK) gene, while it remains unclear whether CTGn may be...
5.
Takada H, Matsumura T, Shimamura H, Matsui M, Kon S, Fukumoto A, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274465
We characterized blood glucose fluctuations in patients with myotonic dystrophy type 1 (DM1). After confirming the incretin secretion capacity of patients with DM1, we intended to clarify whether dipeptidyl peptidase...
6.
Kubo K, Oie Y, Koto R, Nishida N, Kai C, Maeno S, et al.
Cornea
. 2024 Aug;
44(4):412-417.
PMID: 39167633
Purpose: To analyze the corneal phenotypes of Japanese patients with myotonic dystrophy type 1 (DM1). Methods: We included patients with DM1 who were diagnosed with clinical neuromuscular symptoms by neurologists...
7.
Kubota T, Nagata M, Takagi K, Ishihara Y, Kojima K, Uchikura Y, et al.
J Hum Genet
. 2024 Aug;
70(1):3-8.
PMID: 39164360
Hydrops fetalis, characterized by abnormal fluid accumulation in fetuses, presents a significant risk of stillbirth and neonatal mortality. Although the etiology of nonimmune hydrops fetalis (NIHF) is multifaceted, recent studies...
8.
Sugimoto T, Suzuki S, Uzawa A, Yamawaki T, Masuda M, Minami N, et al.
J Neurol Sci
. 2024 Aug;
464:123154.
PMID: 39142082
Introduction/aims: The common presentations of statin intolerance are muscle-specific symptoms. Although statins are one type of drug reported to cause myasthenic worsening, myasthenic worsening has not been recognized as statin...
9.
Kanakura M, Kihara K, Kinoshita M, Sugimoto T, Murata H, Beppu S, et al.
Clin Neurol Neurosurg
. 2024 Jun;
243:108378.
PMID: 38901377
Objectives: This study aimed to evaluate whether switching disease-modifying therapies (DMTs) from sphingosine-1 phosphate (S1P) receptor modulators to either natalizumab (NTZ) or dimethyl fumarate (DMF) could restore the effectiveness of...
10.
Suzuki N, Mori-Yoshimura M, Katsuno M, Takahashi M, Yamashita S, Oya Y, et al.
J Neurol Neurosurg Psychiatry
. 2024 Jun;
95(11):1093-1094.
PMID: 38839274
No abstract available.